ROBERT P KIMBERLY, MD
Osteopathic Medicine at 19 St, Birmingham, AL
License number
Alabama 20592
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
619 19Th St SOUTH, Birmingham, AL 35233
Phone
(205) 934-6600
(205) 731-9701
(205) 731-9701
Personal information
See more information about ROBERT P KIMBERLY at radaris.comName
Address
Phone
17 Ridge Dr, Mountain Brk, AL 35213
Organization information
See more information about ROBERT P KIMBERLY at bizstanding.comUab Medicine Pulmonary - Robert P Kimberly MD
2000 6 Ave S, Birmingham, AL 35233
Categories:
Physicians & Surgeons, Rheumatology Physicians & Surgeons
Site:
Phone:
(205) 996-7438 (Phone)
Additional:
Appointment Line
Uab Highlands - Robert P Kimberly MD
1201 11 Ave S, Birmingham, AL 35205
Categories:
Rheumatology Physicians & Surgeons
Phone:
(205) 934-9999 (Phone)
Rheumatology & Clinical - Robert P Kimberly MD
Birmingham, AL 35233
Categories:
Physicians & Surgeons, Rheumatology Physicians & Surgeons
Phone:
(205) 996-7483 (Phone)
Professional information
See more information about ROBERT P KIMBERLY at trustoria.com
Agents And Methods Related To Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists
Agents And Methods Related To Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists
US Patent:
8129124, Mar 6, 2012
Filed:
Jan 31, 2006
Appl. No.:
11/814551
Inventors:
Tong Zhou - Birmingham AL, US
Robert P. Kimberly - Birmingham AL, US
Robert P. Kimberly - Birmingham AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
G01N 33/53, G01N 33/566, C07K 14/715, C07K 14/47, C07K 14/52
US Classification:
435 71, 435 721, 530350, 530300
Abstract:
Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.
Combinations Of Antibodies Selective For Dr5 And Other Therapeutic Agents
Combinations Of Antibodies Selective For Dr5 And Other Therapeutic Agents
US Patent:
7704502, Apr 27, 2010
Filed:
May 22, 2007
Appl. No.:
11/752153
Inventors:
Tong Zhou - Birmingham AL, US
Kimihisa Ichikawa - Kanagawa-ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Jun Ohsumi - Kanagawa-ken, JP
Albert F. LoBuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Kimihisa Ichikawa - Kanagawa-ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Jun Ohsumi - Kanagawa-ken, JP
Albert F. LoBuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
A61K 39/395, C07K 16/28, C07K 16/30
US Classification:
4241431, 4241381, 5303871, 53038822, 5303888, 530350, 53038885
Abstract:
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Combinations Of Dr5 Antibodies And Other Therapeutic Agents
Combinations Of Dr5 Antibodies And Other Therapeutic Agents
US Patent:
7279160, Oct 9, 2007
Filed:
Oct 25, 2002
Appl. No.:
10/281479
Inventors:
Tong Zhou - Birmingham AL, US
Kimihisa Ichikawa - Kanagawa-Ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Jun Ohsumi - Kanagawa-ken, JP
Albert F. Lobuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Kimihisa Ichikawa - Kanagawa-Ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Jun Ohsumi - Kanagawa-ken, JP
Albert F. Lobuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
C07K 16/28, C07K 16/30, A61K 39/395
US Classification:
4241431, 4241381, 5303871, 53038822, 5303888, 530350, 53038885
Abstract:
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Agents And Methods Related To Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists
Agents And Methods Related To Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists
US Patent:
2013032, Dec 5, 2013
Filed:
May 31, 2013
Appl. No.:
13/907035
Inventors:
Tong Zhou - Birmingham AL, US
Robert P. Kimberly - Birmingham AL, US
Robert P. Kimberly - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
G01N 33/574, C12Q 1/68
US Classification:
506 9, 435 723, 435 613
Abstract:
Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 17, 2012
Appl. No.:
13/621383
Inventors:
Tong Zhou - Birmingham AL, US
Kimihisa Ichikawa - Kanagawa-ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Kimihisa Ichikawa - Kanagawa-ken, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
C07K 16/30, G01N 33/68
US Classification:
4241391, 5303879, 536 2353, 4353201, 435331, 435 696, 435 723
Abstract:
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Genetic Polymorphism In A Complement Receptor
Genetic Polymorphism In A Complement Receptor
US Patent:
2004012, Jun 24, 2004
Filed:
Dec 9, 2003
Appl. No.:
10/731749
Inventors:
Robert Kimberly - Birmingham AL, US
International Classification:
C12Q001/68, G01N033/53, G01N033/567
US Classification:
435/006000, 435/007200
Abstract:
A method and a package for identifying single nucleotide polymorphisms in complement receptor is useful in identifying individual susceptibility to a disease. Complement receptors CR1 and CR2 are active in the immune response and autoimmune diseases. The susceptibility and severity of autoimmune disease is determined by genotyping or phenotyping an individual for complement receptor.
Genetic Polymorphism In The Receptor For Iga
Genetic Polymorphism In The Receptor For Iga
US Patent:
6986987, Jan 17, 2006
Filed:
Jul 23, 1999
Appl. No.:
09/744373
Inventors:
Robert P. Kimberly - Birmingham AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
435 6, 435 912, 536 235, 536 2431, 536 2433
Abstract:
A method and a package for identifying single nucleotide polymorphisms in FcαRI is useful in identifying individual susceptibility to a disease. FcαRI is active as a cellular receptor of IgA. The susceptibility and severity of an IgA related disease is determined by genotyping or phenotyping an individual for FcαRI.
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
US Patent:
8067001, Nov 29, 2011
Filed:
Jun 24, 2010
Appl. No.:
12/822732
Inventors:
Tong Zhou - Birmingham AL, US
Kimishisa Ichikawa - Yokohama, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Kimishisa Ichikawa - Yokohama, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
A61K 39/395, C07K 16/28, C07K 16/30
US Classification:
4241431, 4241381, 5303871, 53038822, 5303888, 530350, 53038885
Abstract:
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
Antibody Selective For A Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor And Uses Thereof
US Patent:
7244429, Jul 17, 2007
Filed:
May 2, 2001
Appl. No.:
10/275180
Inventors:
Tong Zhou - Birmingham AL, US
Kimihisa Ichikawa - Yokohama, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Kimihisa Ichikawa - Yokohama, JP
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
C07K 16/28, C07K 16/30, C12N 15/13, C07K 14/705
US Classification:
4241431, 4241381, 536 2353, 5303871, 53038822, 5303888, 530350, 435334, 435344
Abstract:
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Antibody Selective For Dr4 And Uses Thereof
Antibody Selective For Dr4 And Uses Thereof
US Patent:
2009020, Aug 20, 2009
Filed:
Aug 7, 2008
Appl. No.:
12/187818
Inventors:
Tong Zhou - Birmingham AL, US
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Albert F. LoBuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Robert P. Kimberly - Birmingham AL, US
William J. Koopman - Indian Springs AL, US
Albert F. LoBuglio - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 39/395, C07K 16/00, C07K 16/28, C12N 5/02, C12N 13/00
US Classification:
4241301, 5303871, 53038822, 5303877, 5303873, 435375, 4351731
Abstract:
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.